APA (7th ed.) Citation

AB, A., T, P., B, E., M, B., J, Z., B, S., . . . TK, C. (2022). Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. European journal of cancer (Oxford, England : 1990), 177, 63. https://doi.org/10.1016/j.ejca.2022.09.020

Chicago Style (17th ed.) Citation

AB, Apolo, Powles T, Escudier B, Burotto M, Zhang J, Simsek B, Scheffold C, Motzer RJ, and Choueiri TK. "Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients with Previously Untreated Advanced Renal Cell Carcinoma: Results from a Discontinued Arm of the Phase III CheckMate 9ER Trial." European Journal of Cancer (Oxford, England : 1990) 177 (2022): 63. https://doi.org/10.1016/j.ejca.2022.09.020.

MLA (9th ed.) Citation

AB, Apolo, et al. "Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients with Previously Untreated Advanced Renal Cell Carcinoma: Results from a Discontinued Arm of the Phase III CheckMate 9ER Trial." European Journal of Cancer (Oxford, England : 1990), vol. 177, 2022, p. 63, https://doi.org/10.1016/j.ejca.2022.09.020.